http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110396122-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J63-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D475-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J43-003 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D475-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J63-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-10 |
| filingDate | 2019-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110396122-B |
| titleOfInvention | Nuclear magnetic resonance contrast agent, preparation method and use thereof in tumor diagnosis |
| abstract | A nuclear magnetic resonance contrast agent is provided, its structure is as shown in formula I, wherein, n is an integer of 1-3; L A -COOH is any one in glycyrrhetinic acid, cholic acid, folic acid, and the compound has a It is a kind of effective MRI contrast agent for tumor diagnosis due to the advantages of high helicity rate, good targeting to tumors, especially liver tumors, and low dose. |
| priorityDate | 2019-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.